SERTEX Trademark

Trademark Overview

On Thursday, November 20, 2014, a trademark application was filed for SERTEX with the United States Patent and Trademark Office. The USPTO has given the SERTEX trademark a serial number of 79159937. The federal status of this trademark filing is IR CANCELLED - US APPLICATION ABANDONED as of Friday, December 18, 2015. This trademark is owned by JEFARMA GmbH. The SERTEX trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the treatment of depression, sedatives, and mood stabilizers
sertex

General Information

Serial Number79159937
Word MarkSERTEX
Filing DateThursday, November 20, 2014
Status402 - IR CANCELLED - US APPLICATION ABANDONED
Status DateFriday, December 18, 2015
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 22, 2015

Trademark Statements

Goods and Servicespharmaceutical preparations for the treatment of depression, sedatives, and mood stabilizers

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeH - NOT AVAILABLE
Class Status DateFriday, December 18, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameJEFARMA GmbH
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDE
Party NameJEFARMA GmbH
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDE

Trademark Events

Event DateEvent Description
Monday, January 25, 2016OPPOSITION TERMINATED NO. 999999
Monday, January 25, 2016OPPOSITION SUSTAINED NO. 999999
Tuesday, January 5, 2016NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Monday, January 4, 2016DEATH OF INTERNATIONAL REGISTRATION
Tuesday, November 17, 2015REFUSAL PROCESSED BY IB
Saturday, October 24, 2015OPPOSITION INSTITUTED NO. 999999
Thursday, October 22, 2015OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Thursday, October 22, 2015OPPOSITION NOTICE (IB REFUSAL) CREATED
Wednesday, October 21, 2015OPPOSITION PAPERS RECEIVED AT TTAB
Tuesday, September 22, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 22, 2015PUBLISHED FOR OPPOSITION
Friday, September 18, 2015NOTIFICATION PROCESSED BY IB
Wednesday, September 2, 2015NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 2, 2015NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, September 2, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, August 16, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Sunday, August 16, 2015ASSIGNED TO LIE
Monday, August 3, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 31, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 31, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 31, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 6, 2015LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
Monday, July 6, 2015LETTER OF PROTEST EVIDENCE FORWARDED
Sunday, May 31, 2015NEW REPRESENTATIVE AT IB RECEIVED
Saturday, April 4, 2015REFUSAL PROCESSED BY IB
Thursday, March 19, 2015NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, March 19, 2015REFUSAL PROCESSED BY MPU
Thursday, March 19, 2015NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, March 18, 2015NON-FINAL ACTION WRITTEN
Wednesday, March 11, 2015ASSIGNED TO EXAMINER
Tuesday, February 17, 2015APPLICATION FILING RECEIPT MAILED
Friday, February 13, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, February 12, 2015SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

sertex mood stabilizers sedatives depression preparations treatment pharmaceutical